Seagen Inc.
SGENDrugs in Pipeline
28
Phase 3 Programs
9
Upcoming Catalysts
2
Next Catalyst
Dec 31, 2026
43wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Adcetris
Brentuximab Vedotin
Hodgkin Lymphoma
tucatinib
Gastric Adenocarcinoma
doxorubicin
Anaplastic Large-Cell Lymphoma
Trastuzumab
Metastatic Colorectal Adenocarcinoma
brentuximab vedotin
Lymphoma, B-Cell
Padcev
Enfortumab Vedotin
Urothelial Cancer
sigvotatug vedotin
Carcinoma, Non-Small-Cell Lung
gemcitabine
Urothelial Carcinoma
Lenalidomide
Diffuse Large B-cell Lymphoma
disitamab vedotin
Breast Neoplasms
dacarbazine
Hodgkin Disease
nivolumab
Hodgkin Lymphoma
Tisotumab Vedotin (HuMax-TF-ADC)
Ovary Cancer
Lintuzumab (SGN-33)
Acute Myeloid Leukemia
ladiratuzumab vedotin
Triple Negative Breast Neoplasms
SGN-15, Docetaxel
Non-Small Cell Lung Carcinoma
tisotumab vedotin
Ovarian Cancer
SGN-30
Large Cell Lymphoma
carboplatin
Colorectal Neoplasms
SGN-40 (anti-huCD40 mAb)
Leukemia, Lymphocytic, Chronic
Tukysa
Tucatinib
HER2+ Breast Cancer
SGN-40
Lymphoma, Large B-Cell, Diffuse
SGN-30 (monoclonal antibody)
Hodgkin Disease
SGN-15 (cBR96-doxorubicin immunoconjugate)
Prostatic Neoplasms
bendamustine
Hodgkin Disease
SGN-15
Carcinoma, Non-Small-Cell Lung
SGN-30 (anti-CD30 mAb)
Anaplastic Large-Cell Lymphoma
SEA-CD40
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adcetris Brentuximab Vedotin | Approved | Hodgkin Lymphoma | Orphan | - |
tucatinib | Phase 3 | Gastric Adenocarcinoma | - | Patent 2038 |
doxorubicin | Phase 3 | Anaplastic Large-Cell Lymphoma | - | - |
Trastuzumab | Phase 3 | Metastatic Colorectal Adenocarcinoma | - | |
brentuximab vedotin | Phase 3 | Lymphoma, B-Cell | - | - |
Padcev Enfortumab Vedotin | Phase 3 | Urothelial Cancer | Fast TrackBreakthrough | - |
sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
gemcitabine | Phase 3 | Urothelial Carcinoma | - | - |
Lenalidomide | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
disitamab vedotin | Phase 3 | Breast Neoplasms | - | - |
dacarbazine | Phase 2 | Hodgkin Disease | - | |
nivolumab | Phase 2 | Hodgkin Lymphoma | - | - |
Tisotumab Vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
Lintuzumab (SGN-33) | Phase 2 | Acute Myeloid Leukemia | - | - |
ladiratuzumab vedotin | Phase 2 | Triple Negative Breast Neoplasms | - | - |
SGN-15, Docetaxel | Phase 2 | Non-Small Cell Lung Carcinoma | - | Patent 2036 |
tisotumab vedotin | Phase 2 | Ovarian Cancer | - | - |
SGN-30 | Phase 2 | Large Cell Lymphoma | - | - |
carboplatin | Phase 2 | Colorectal Neoplasms | - | - |
SGN-40 (anti-huCD40 mAb) | Phase 2 | Leukemia, Lymphocytic, Chronic | - | - |
Tukysa Tucatinib | Phase 2 | HER2+ Breast Cancer | Fast TrackBreakthrough | Patent 2038 |
SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
SGN-30 (monoclonal antibody) | Phase 2 | Hodgkin Disease | - | - |
SGN-15 (cBR96-doxorubicin immunoconjugate) | Phase 2 | Prostatic Neoplasms | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SGN-30 (anti-CD30 mAb) | Phase 2 | Anaplastic Large-Cell Lymphoma | - | - |
SEA-CD40 | Phase 2 | Melanoma | - | - |
Hodgkin Disease
3 drugs in this indication
Hodgkin Lymphoma
2 drugs in this indication
Anaplastic Large-Cell Lymphoma
2 drugs in this indication
HER2+ Breast Cancer
1 drug in this indication
Lymphoma, Large B-Cell, Diffuse
1 drug in this indication
Prostatic Neoplasms
1 drug in this indication
Metastatic Colorectal Adenocarcinoma
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Gastric Adenocarcinoma
1 drug in this indication
Large Cell Lymphoma
1 drug in this indication
Lymphoma, B-Cell
1 drug in this indication
Ovary Cancer
1 drug in this indication
Non-Small Cell Lung Carcinoma
1 drug in this indication
Leukemia, Lymphocytic, Chronic
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Melanoma
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Disease, Hodgkin
1 drug in this indication
Triple Negative Breast Neoplasms
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)